Ibuprofen
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Ibuprofen: From Pain and Inflammation to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ibuprofen is a widely used NSAID for pain, inflammation, and fever. The TxGNN model predicts it may be effective for Acromesomelic Dysplasia, Hunter-Thompson Type, a rare autosomal-recessive skeletal disorder — but this is a model-score-only prediction (L5), with 0 clinical trials and 0 publications currently supporting this direction, and the evidence pack’s own mechanistic rationale states there is no known biological link between ibuprofen’s mechanism and this disease’s pathology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in this evidence pack (no original_indications or license records available) |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only) |
| Market Status (this jurisdiction) | Not marketed (0 licenses on file) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1/COX-2), reducing prostaglandin synthesis to relieve pain, inflammation, and fever.
However, the mechanistic rationale supplied with this prediction explicitly undermines the biological case: Acromesomelic Dysplasia, Hunter-Thompson Type is caused by GDF5 gene mutations that disrupt cartilage-formation signaling — a structural/developmental disorder, not an inflammatory one. The rationale states ibuprofen has “no direct mechanistic link to the disease-causing pathway,” and could at most relieve secondary joint pain rather than modify the disease itself.
In other words, the high TxGNN score (99.74%) reflects graph-embedding similarity in the knowledge graph, not a validated pharmacological mechanism. This pattern repeats across all seven top-ranked candidates in this pack (brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, brachyolmia, brachydactyly-syndactyly syndrome, pseudoachondroplasia, colobomatous microphthalmia-rhizomelic dysplasia syndrome) — all are rare genetic/structural skeletal or developmental disorders, and each rationale independently notes the absence of an inflammatory mechanism connecting them to ibuprofen.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
No license records found. Per the evidence pack, this drug is not currently marketed in this jurisdiction (0 approved licenses), so no product/dosage-form table can be produced.
Safety Considerations
Please refer to the package insert for safety information.
(Note: a Blocking-severity data gap exists — TFDA-equivalent label warnings/contraindications could not be retrieved, which by itself prevents this candidate from clearing the S1 safety-review stage regardless of efficacy evidence.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but evidence level is L5 (model output only) — no clinical trials, no literature, no mechanistic support (the pack’s own rationale states the target disease pathology is non-inflammatory and structurally/genetically driven). Combined with a Blocking data gap on safety labeling and zero market licenses for this drug in this jurisdiction, there is no basis to advance past S0.
To proceed, the following is needed:
- Regulatory label data (warnings/contraindications) — currently Blocking (DG001)
- Confirmed mechanism of action data — currently High severity gap (DG002)
- Original indication and licensing records for this drug in this jurisdiction
- Any preclinical or case-level evidence specifically linking NSAID/COX-inhibition to GDF5-pathway skeletal dysplasias, before this direction is pursued further
All other top-7 predicted indications in this pack show the same profile (L5, no trials/literature, no mechanistic support, Hold recommendation) and are not expected to change this conclusion.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.